Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAblindependent drug that can be combined with a TKI to improve overall disease response in chronic-phase CML. Omacetaxine mepesuccinate, a first in class cetaxine, has been evaluated by clinical trials in TKI-insensitive/resistant CML. Omacetaxine inhibits synthesis of anti-apoptotic proteins of the Bcl-2 family, including (myeloid cell leukaemia) Mcl-1, leading to cell death. Omacetaxine effectively induced apoptosis in primary CML stem cells (CD34 þ 38 lo ) by downregulation of Mcl-1 protein. In contrast to our previous findings with TKIs, omacetaxine did not accumulate undivided cells in vitro. Furthermore, the functionality of surviving stem cells following omacetaxine exposure was significantly reduced in a dose-dependant manner, as determined by colony forming cell and the more stringent long-term culture initiating cell colony assays. This stem cell-directed activity was not limited to CML stem cells as both normal and non-CML CD34 þ cells were sensitive to inhibition. Thus, although omacetaxine is not leukaemia stem cell specific, its ability to induce apoptosis of leukaemic stem cells distinguishes it from TKIs and creates the potential for a curative strategy for persistent disease.
Introduction
Omacetaxine mepesuccinate (ChemGenex Pharmaceuticals Inc., Menlo Park, CA, USA), a first in class cetaxine, is a semisynthetic alkaloid that has demonstrable activity in clinical trials in acute myeloid leukaemia, myelodysplastic syndrome, as well as in chronic myeloid leukaemia (CML). 1 However, with the continued success of tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib and dasatinib, as first-and second-line treatment for CML, the role of omacetaxine has been restricted to niche indications, including failure of two or more TKI or with the TKI-insensitive mutation, T315I, against which all currently licensed TKI are ineffective. Omacetaxine is a semisynthetic, subcutaneously bioavailable form of homoharringtonine. Homoharringtonine was used in second-line therapy for those CML patients in the pre-TKI era of the 1990s who failed interferon-a therapy and were ineligible for a transplant 2, 3 Therefore this product has, for a second time, become a valuable option in the treatment of resistant disease. Moreover, the demonstration that omacetaxine can kill leukaemic stem cells in murine models 4 has allowed the drug to be considered as a therapeutic option for both persistent and resistant disease.
Homoharringtonine (from here is referred to as omacetaxine) is derived from various Cephalotaxus species (Chinese yew tree) and was first discovered by the Chinese to have natural antitumour and anti-leukaemic properties in the 1970s. 5, 6 Recent work has elucidated a mechanism of action targeted to the A-site cleft of eukaryotic ribosomes 7 resulting in transient inhibition of protein synthesis of short-lived proteins, such as myeloid cell leukaemia (Mcl-1) protein (a highly expressed member of the Bcl-2 family of anti-apoptotic proteins), leading to apoptosis. 8 Further, it has been shown that Mcl-1 has a critical role in the survival of leukaemia cells and its expression is upregulated with respect to normal. 9, 10 As such, omacetaxine acts independently of BcrAbl kinase activity, the causative oncoprotein in CML. Taken together with a recently reported ability to kill stem cells, 4 omacetaxine could therefore be an interesting therapeutic modality in minimal residual disease in CML, where the continued detection of BcrAbl transcripts is thought to originate from the stem cell compartment, 11 and leukaemic stem cell survival may be BcrAbl independent. 12 Therefore, the aim of our study was to assess the activity of omacetaxine against CML stem/progenitor cells in vitro in order to identify potential ways of eradicating persistent disease. Sequential clinical samples from newly diagnosed cases were selected for assay and were not subject to mutation analysis. We have previously shown CML CD34 þ cells to be insensitive to TKI by virtue of their quiescence and primitive phenotype. From our on-going work and that of others, it is our belief that CML stem cells may not be oncogene addicted (that is, dependant on BcrAbl for their survival), and thus any novel agents or novel indications for existing molecules with targeting potential at the (stem) cell level to complement TKI modalities is of significant interest.
Materials and methods

Reagents
Omacetaxine mepesuccinate, supplied by ChemGenex Pharmaceuticals , was stored lyophilised at room temperature; once reconstituted in saline to 10 mM, the stock solution was stored at 4 1C for up to 3 months.
Cell culture
Primary CML cells were obtained with informed consent from leukapheresis samples of newly diagnosed patients with chronic-phase CML or Ph À haematological disorders (for example, lymphoma) as controls. CD34 þ cells enriched by positive selection (CliniMACS, Miltenyi Biotec Ltd., Bisley, Surrey, UK) according to the manufacturer's instructions to 495% purity were cryopreserved in 10% (v/v) dimethylsulphoxide in 4% (w/v) ALBA (human albumin solution, Scottish National Blood Transfusion Service, Edinburgh, UK) and stored in the vapour phase of liquid nitrogen until required. CD34 þ cells were cultured in serum-free media comprising Iscove's modified Dulbecco's medium with BIT (bovine serum albumin, insulin, transferrin; Stem Cell Technologies, Vancouver, BC, Canada), 1 mmol/l glutamine, 1 mmol/l streptomycin/penicillin, 40 ng/ml low-density lipoprotein and 0.1 mmol/l 2-mercaptoethanol (all, Invitrogen Ltd, Paisley, UK), further supplemented with a 5-growth factor cocktail as previously described. 13 The BcrAbl-positive human myeloid cell lines, K562 and KCL22 were maintained in RPMI 1640 (Sigma-Aldrich, Poole, Dorset, UK) supplemented with 10% (v/v) foetal calf serum containing 1 mmol/l each of streptomycin, penicillin and glutamine (RPMI þ ). Total cell counts and viability were assessed using the trypan blue dye exclusion method.
Flow cytometry
Apoptosis. To assess apoptosis after drug treatment, an aliquot of cell suspension containing 1-2 Â 10 5 cells was removed for staining with Annexin V-fluorescein isothiocyanate and Viaprobe (BD Biosciences, Oxford, UK) as per the manufacturer's instructions and analysed by flow cytometry using a BD FACS Canto with Diva software. Cells undergoing apoptosis initially become Annexin V positive (early apoptosis), and as apoptosis progresses, become positive for both Annexin V and Viaprobe (late apoptosis).
Cell division tracking
Upon recovery from liquid nitrogen, CML CD34 þ cells were stained with 1 mM carboxy-fluorescein diacetate succinimidyl diester (CFSE; Molecular Probes, Invitrogen Ltd, Paisley, UK), as described previously in detail.
14 Cells were then cultured in serum-free media þ 5-growth factor in the presence or absence of omacetaxine for 24 or 72 h. After 3 days, cells were harvested, total cell viability assessed, and an aliquot of cells from each treatment stained with anti-CD34-PE antibody (BD Pharmingen) for flow cytometry analysis. Cells cultured with 100 ng/ml Colcemid (Invitrogen), which arrests cell-cycle progression, were used to identify the undivided (CFSE max ) cell population.
To measure the overall effect of the treatments on cell survival and the number of undivided cells remaining after culture with omacetaxine, the percentage recovery of CD34 þ cells in the undivided CFSE max peak was calculated with respect to the input as previously described 13 and expressed as a proportion of the no drug control (NDC). Briefly, the number of CD34 þ cells used to establish each culture was recorded. After the 3-day culture period, the total number of viable cells harvested from each culture condition was recorded, as were the percentages of viable CD34 þ cells found in the undivided fraction and in each division peak from the CFSE/CD34 þ flow cytometry plots. Percentage recovery of input cells in each peak could then be calculated by dividing the absolute number of CD34 þ viable cells in each peak on day 3, corrected for cell division by the total number of input CD34 þ cells and multiplying by 100. Note, although the percentage in the CFSE max CD34
þ peak may increase with omacetaxine treatment, because of a very significant reduction in total cells (undivided plus proliferating cells), the absolute number of undivided cells (product of % Â total cell number) may remain unchanged. LTC-IC assays were set up as previously described. 15 Briefly, M2-10B4 cells and SL/SL fibroblasts were established as feeder layers then irradiated at 80 Gy. CML cells remaining in culture after drug treatment were washed three times and then plated in duplicate on the irradiated feeder layers in Myelocult medium supplemented with hydrocortisone at a final concentration of 1 mM (Stem Cell Technologies). Cultures were maintained for 5 weeks with weekly half medium changes. After 5 weeks, cells were counted and 2.5 Â 10 4 cells were transferred to CFC assays and maintained in culture for a further 2 weeks in Methocult medium before the colonies were counted.
Primitive subsets
Western blotting
Following treatment with drugs, K562 and primary CML cells (2-5 Â 10 6 ) were pelleted by centrifugation, washed twice with ice-cold phosphate-buffered saline, and then lysed in buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, plus protease inhibitors (complete mini protease inhibitor cocktail tablets; Roche Diagnostics, Burgess Hill, UK). Protein lysates were separated on 4-15% Tris-HCl gradient gels (Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, UK), transferred onto nitrocellulose membrane (Bio-Rad Laboratories), and blocked with 5% bovine serum albumin in Tris-buffered saline (0.1%) Tween 20 for 1 h at room temperature. Membranes were incubated with primary antibody overnight at 4 1C: poly(ADP-ribose) polymerase, Mcl-1, GAPDH (Cell Signalling, New England Biolabs (UK) Ltd, Hertfordshire, UK), abl, Bcl-2, Bcl-2-interacting mediator of cell death (BD Biosciences) at 1:1000 and anti-heat-shock protein 90 (R&D Systems, Abingdon, UK) at 1:10 000 in 1% bovine serum albumin/Tris-buffered saline Tween 20. Membranes were then washed five times with Tris-buffered saline Tween 20 and then incubated with horseradish peroxidase-labelled secondary antibody at 1:3000 in 1% bovine serum albumin/Tris-buffered saline Tween 20 for 1 h at room temperature. Antibody detection was performed using enhanced chemiluminescence reagent (Immun-Star Western C Kit, Bio-Rad) and visualised in a ChemiDoc illuminator (Bio-Rad Laboratories) with Quantity 1 image capture software (Bio-Rad Laboratories, Hercules, CA, USA).
Results
Omacetaxine potently inhibits growth of K562, primary CML CD34
þ and non-CML CD34 þ cells in vitro
The drug concentration required to reduce cell numbers to 50% of the NDC (IC 50 ) was determined by viable cell counts for K562, CML CD34 þ and non-CML CD34 þ cells at 24-h intervals over 3 days (Figure 1 ). The mean IC 50 values for omacetaxine-treated K562 in three independent experiments were 41000, 35 and 35 nM at 24, 48 and 72 h, respectively ( Figure 1a ). Primary CML CD34 þ cells were more sensitive to omacetaxine treatment than K562 with IC 50 values of 40, 4 and 2.8 nM at 24, 48 and 72 h, respectively (n ¼ 3; Figure 1b ). The omacetaxine effect appeared to be stem/progenitor cell directed as it produced similar IC 50 values of 20, 4.5 and 3.5 nM at 24, 48 and 72 h, respectively, with non-CML CD34 þ cells (n ¼ 2; Figure 1c ).
The minimum exposure to omacetaxine required to inhibit cell growth by 450% and induce apoptosis in CD34
þ cells is 24h
CML CD34 þ cells were cultured with and without omacetaxine in serum-free media þ 5-growth factor for various time points from 15 min to 72 h ( Figure 2 ), after which cells were washed free of drug and re-seeded in fresh serum-free media þ 5-growth factor. Omacetaxine was used in this experiment at 10 and 100 nM, being in the approximate range of the calculated IC 50 values ( Figure 1 ) and clinically achievable concentrations (personal communication with ChemGenex). Cells were counted after a total of 72 h in culture for all samples and stained with Annexin V/Viaprobe to measure apoptosis. Total viable cells were expressed as trypan blue cell counts multiplied by the percentage cells, which were negative for Annexin V/Viaprobe. Treatment of CML CD34 þ cells with 100 nM omacetaxine for only 6 h reduced viable cell numbers at 72 h to 50% of NDC. However a minimum of 24-h exposure to either 10 or 100 nM omacetaxine was required to significantly reduce viable cell numbers to greater than 50% with respect to 15-min drug treatment (Figure 2a ; Po0.001; n ¼ 3) (as NDC had been normalised to 100% in each experiment, there was no deviation and therefore statistics were generated with respect to the next time point). Omacetaxine (100 nM) effectively induced apoptosis in CML CD34 þ cells after just 24-h treatment in 58% of cells as measured by the total cells staining positive for Annexin V at 72 h; however, prolonged 72-h drug treatment at this concentration resulted in almost all cells (90%) undergoing apoptosis (Figure 2b ). CD34 þ cells from a myeloma patient (non-CML control) that had been treated with 10 nM omacetaxine for 24 h reduced in viable cell count to only 17% of the NDC (Figure 2c ) and to a similar degree to CML CD34 þ cells, again suggesting a stem/progenitor cell-directed effect of the drug. Treatment of non-CML CD34 þ cells induced similar levels of apoptosis as for CML (Figure 2d ).
Omacetaxine does not accumulate cells in the undivided fraction
Although omacetaxine was clearly inducing apoptosis in CML CD34 þ cells in vitro, an effect not observed with TKIs, 13, 16, 17 we next sought to determine whether omacetaxine was antiproliferative against the stem/progenitor cell compartment, leading to arrest of cell-cycle progression or block of cell division in a proportion of cells without killing. This was done using flow cytometry with CFSE staining to facilitate analysis of cell-division history. 14 with increasing omacetaxine concentration, at 24 h, there was a dose-dependant significant reduction in the total number of CD34 þ cells recovered with respect to the NDC (Figure 3ci , *Po0.05, ***Po0.001). The fold change in recovery of input of undivided CD34 þ cells is calculated as the product of the percentage in the undivided gate (which has increased) times the total CD34 þ cell number (which has decreased through apoptosis). There was no statistically significant change in CML CD34 þ cells recovered in the undivided fraction with respect to NDC with omacetaxine at any of the concentrations tested (Figure 3di ). Although only assayed once in normal granulocyte-colony-stimulating factor -mobilised donor cells, more CD34
þ cells were recovered in all divisions as a percentage of the NDC in comparison with CML with 10 or 50 nM, but not 100 nM omacetaxine ( Figure 3cii) ; moreover, fewer cells were recovered in the undivided fraction in a dosedependant manner relative to NDC (Figure 3dii ) as compared with CML (Figure 3di ).
Omacetaxine and stem/progenitor cell functionality Although, encouragingly, it appeared that omacetaxine activity in vitro was stem/progenitor cell directed in that the drug reduced total CD34
þ cell numbers, we were interested to know the stem/ progenitor cell function of any remaining apparently viable CD34 þ cells following treatment. This was assessed in CFC and LTC-IC assays. CFC assays demonstrated that omacetaxine significantly reduced the number of CML and non-CML CFC, in a dose dependant manner with respect to the NDCs (Figure 4a , ***Po0.001). We were also able to confirm in a single sample of normal granulocyte-colonystimulating factor mobilised donor CD34 þ cells that omacetaxine at high concentrations (50 and 100 nM) was cytotoxic for CFC activity to a similar degree as for CML cells.
CFC assays give an indication of committed progenitor cell survival, but for stem cell enumeration, LTC-IC assays are more appropriate. Mirroring the CFC result, omacetaxine reduced the LTC-IC number in CML, non-CML and normal donor CD34 
Scheduled combination of omacetaxine with imatinib improves cell kill in Ph þ cell lines
The Ph þ blast crisis cell line, KCL22, was significantly more sensitive to omacetaxine than to imatinib (Po0.05; Figure 5ai ). Scheduled combination of omacetaxine (20 nM, approximate IC 50 ) with imatinib (0.5 mM) with or without drug washout at 24 h significantly reduced cell viability with respect to omacetaxine alone, when omacetaxine was administered before imatinib (Po0.05; Figure 5ai ). Addition of imatinib first did not achieve increased cell kill with respect to omacetaxine alone. Simultaneous treatment with omacetaxine and imatinib for 72 h was no more effective than omacetaxine alone. In order to determine any combination effect in primary CD34 þ cells, we selected the lowest concentration of omacetaxine (10 nM) as this had shown lesser toxicity by CFC in the normal CD34 þ sample tested previously (Figure 4a ). CML CD34 þ cells were treated with omacetaxine or imatinib (5 mM) or both in combination. When administered together, all of the combinations tested were significantly more effective than treatment with either imatinib (Po0.001) or omacetaxine alone (Po0.05; Figure 5bi ). In contrast to KCL22, treatment of primary CD34 þ cells with omacetaxine and imatinib for 72 h was equally effective whether administered simultaneously or in a scheduled combination (Figure 5bii and iii) . By cell count, apoptosis and colony forming potential, normal donor CD34 þ cells were as sensitive as CML CD34 þ cells to treatment with omacetaxine alone or in combination with imatinib.
Mechanism of action of omacetaxine in Ph þ cells
Increasing concentrations of omacetaxine induced apoptosis in K562 and CML stem/progenitor cells as confirmed by poly(ADPribose) polymerase cleavage and loss of the anti-apoptotic protein, Mcl-1 (Figure 6a ). K562 cells are known to have extremely low expression of Bcl-2 18 and indeed we did not detect this protein by western blotting of lysates from this cell line, but it was found to be unchanged in primary CML CD34 þ cells with omacetaxine treatment (Figure 6b) . Likewise, both the pro-apoptotic Bcl-2-interacting mediator of cell death protein and the molecular chaperone, heat-shock protein 90, were unaffected by omacetaxine treatment as determined by densitometric analysis of western blots with respect to the loading control (GAPDH). heat-shock protein 90 had previously been shown to be lost on omacetaxine treatment in Ph þ cell lines 4 together with loss of BcrAbl protein, which we did not observe ( Supplementary Figures 1 and 2 ).
Omacetaxine induces apoptosis of primitive CML CD34 cell subsets with reduction in Mcl-1 expression
It was of interest to determine the activity of omacetaxine in more primitive subsets of CD34 þ cells. To achieve this, total CML CD34 þ cells were sorted by flow cytometry into three cell fractions (mature CD34 lo 38
þ , CD34 þ 38 þ progenitors and the more primitive CD34 þ 38 lo population). As can be seen in Figure 7 , even the more primitive CD34
þ 38 lo cells that we have previously shown to be insensitive to TKI like imatinib were not spared by omacetaxine, with levels of apoptosis in the same order as mature and progenitor cells (Figure 7a ). Apoptosis was confirmed by cleavage of poly(ADP-ribose) polymerase (Figure 7b ) and was mediated in the same way as in bulk CD34
þ by Mcl-1 downregulation (cf Figure 6 ).
Discussion
Our interests in CML leukaemic stem cell survival in the face of complete BcrAbl kinase inhibition have led us to investigate other agents that exhibit activity at the stem/progenitor cell level and have a mechanism of action that is BcrAbl independent. We considered omacetaxine to be worthy of further investigation with its BcrAbl-independent mechanism of action, acceptable safety in humans and potential for stem cell activity. Figure 4 The clonogenic and stem cell capacity of cells remaining after omacetaxine treatment. (a) CFC: CD34 þ cells were cultured ± omacetaxine in serum-free media (SFM) þ 5-growth factor (5GF) as indicated after which time cells were washed free of drug and added to semisolid culture media to assess colony forming capacity as described in the materials and methods. Colonies were counted and are expressed as a percentage of the NDC for (i) CML (n ¼ 4), (ii) non-CML (n ¼ 2: multiple myeloma and mantle cell lymphoma) and (iii) normal granulocytecolony-stimulating factor-mobilised donor (n ¼ 1). Omacetaxine significantly reduced the colony forming potential of CML and non-CML stem cells, in a dose-and time-dependent manner with respect to the NDC (***Po 0.001) and also reduced colony formation in normal stem cells.
(b) LTC-IC: CD34
þ cells remaining after omacetaxine treatment as in (a) were cultured for 5 weeks on stroma then plated out in CFC as described in the materials and methods. Total colonies were counted for (i) CML (n ¼ 2), (ii) non-CML (n ¼ 2) and (iii) normal CD34 þ (n ¼ 1). primary CML cells were found to be more sensitive to omacetaxine than K562 blast crisis cells, with a significantly lower IC50 in the former. Despite the evidence of efficacy from clinical trials and the known molecular mode of action of omacetaxine, it was only reported very recently 4 that the drug could eliminate 490% of leukaemia stem cells in murine models of BcrAbl þ CML and B-acute lymphoblastic leukemia, whereas TKI (imatinib or dasatinib) achieved less than 25% kill. Interestingly, the kill was seen for both wild-type and T315I mutant BcrAbl. This is a significant result that needs verification in primary material derived from CML patients as cellular context of BcrAbl expression (de novo expression in human stem cells versus retroviral transduction of bone marrow cells from 5-fluorouraciltreated donor mice) may be significant, given the survival mechanisms that may be invoked by stem cells programmed to stay alive.
In an in vitro drug combination study in CML cell lines, 22 it had been suggested that cytosine arabinoside or omacetaxine might act synergistically with imatinib in the case of resistance to imatinib. However, we 16 demonstrated at the stem cell level in vitro that cytosine arabinoside was anti-proliferative in combination with imatinib, resulting in accumulation of stem cells. In our current study, we did not assay omacetaxine in combination in primary CML CD34
þ , but uniquely demonstrated apoptosis in the primitive (CD34 þ 38 lo ) leukaemic cell subpopulation. Thus, the prevention of colony formation by omacetaxine observed by Tipping et al. is most likely the result of CFC loss through death, as opposed to cell-cycle arrest. Of note, if omacetaxine was to be combined with imatinib then there is evidence to suggest that the sequence of exposure would be critical. In one previous study, antagonism was seen with the simultaneous combination 23 in clonogenic assays. However this could be reverted to a cooperative effect, if omacetaxine was pulsed for 24 h before imatinib. Indeed, we have shown in a relatively less imatinib-sensitive cell line (KCL22) 24 to corroborate this latter finding, suggesting that when introduced into the culture before imatinib, omacetaxine is indeed more lethal than the reverse sequence. As omacetaxine is likely to block accumulation of Bcl-2-interacting mediator of cell death, which is critical to imatinib's induction of apoptosis, 25 this may explain the antagonism seen with simultaneous addition of the two drugs. 23 However, the loss of the Bcl-2-interacting mediator of cell death-negative regulator, Mcl-1, on omacetaxine treatment may sensitise the cells to the combined effect of both drugs. Both simultaneous and scheduled permutations of the combination showed parity in toxicity between CML and normal donor CD34 þ cells ( Figure 5 ) at the concentrations selected to be tested. Thus, our results support the BcrAbl-independent stem cell-directed effect of omacetaxine, but predict toxicity in vivo owing to the non-selective killing of both normal and leukaemic cells, which is unlikely to be abrogated through scheduled dosing regimens.
Combinations aside, it is clear from this study that omacetaxine has activity at the primary CML leukaemia stem/progenitor cell level in vitro. Samples were consecutive newly diagnosed cases of CML in chronic phase, in which TKI-resistant mutations are extremely rare and never dominant in the stem cell compartment before evolution under TKI-selection pressure. This may mean that omacetaxine has a potential role in eradicating minimal residual disease achieved in response to TKI, but maintained by persistent, as opposed to overtly resistant leukaemia stem cells. The shortcoming for this agent is toxicity to normal stem cells, which could be predicted from on-going clinical trials in which myelosuppression is a significant issue. Indeed, in vitro toxicity of omacetaxine to Ph À HSC is reported here. The paucity of results in normal donor stem cells is in keeping with the ethical concerns surrounding prolonging stem cell collections for the purposes of research from healthy individuals over and above the required clinical dose, hence the decision to assay more readily available Ph À non-CML CD34 þ cells from diseases in which the HSC is not implicated.
A number of reports have been made recently demonstrating stem cell activity of novel agents for use in CML (for example, farnesyl transferase inhibitors (for example, BMS-214662), 15 histone deacetylase inhibitors (for example, LBH589), 26 autophagy inhibitors (for example, chloroquine), 27 proteasome inhibitors (for example, bortezomib 28 ). Clearly, there is considerable interest in the field to uncover a suitable partner to kinase inhibition to think in terms of cure for CML. Omacetaxine, however, is the most advanced in its clinical development. Omacetaxine effectively induces apoptosis in primary CML stem cells through downregulation of Mcl-1 and independent of BcrAbl. This mechanism of action could explain at least some of its clinical activity and allow omacetaxine to be considered as an option in the management of minimal residual disease in CML.
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